Brief: Xencor Presents Data From Phase 1 Study Of Plamotamab In B-Cell Non-Hodgkin Lymphomas At ASH Annual Meeting
12/12/2021 15:13
Dec 12 (Reuters) - Xencor Inc XNCR.O :
* XENCOR PRESENTS DATA FROM PHASE 1 STUDY OF PLAMOTAMAB IN
B-CELL
NON-HODGKIN LYMPHOMAS AT ASH ANNUAL MEETING
Source text for Eikon: ID:nBwccqgcsa
Further company coverage: XNCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xencor
See all newsXencor, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments
Brief: Xencor Q2 EPS USD -0.29
Brief: Xencor To Receive $105 Million From Alexion To Resolve Ultomiris® U.S. Royalty Matter
Xencor Q1 revenue falls sharply and misses estimates